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Abstract
Background: In damaged organs tissue repair and replacement of cells by connective tissue provokes a response
of fibroblasts to cellular stress factors such as hypoxia.
MicroRNAs (miRNA) are small non-coding RNA molecules which bind to their mRNA targets which eventually lead
to repression of translation. Whether the response of fibroblasts to stress factors also involves the miRNA system is
largely unknown.
Results: By miRNA profiling we identified down-regulation of miRNA-449a/b expression in hypoxic fibroblasts.
Specific miRNA inhibitors and mimics showed direct evidence for targeting the serine protease inhibitor (serpin)
protein (SERPINE1; plasminogen activator inhibitor-1, PAI-1) by miRNA-449a/b leading to SERPINE1 mRNA and
protein up- and down-regulation, respectively. SERPINE1 expression in vivo could be located predominantly in areas
of fibrosis and remodeling.
Conclusions: Our study offers serious lines of evidence for a novel hypoxia-dependent mechanism involving
hypoxia-induced decrease of clustered miRNA-449a/b, hypoxia-induced amplification of concomitant increase of
targeted SERPINE1 (PAI-1) and its overexpression in tissues showing a hypoxic environment.
Background
Extracellular matrix (ECM) deposition and fibrotic
remodeling in damaged tissues is the principle to regain
integrity when affected tissues have no or only limited
capability for self-renewal [1]. Damage of tissues and
cells can be induced by hypoxia, infections and chronic
irritants but has in common that the response to injury
is very similar. Mechanisms of reparation will take place
after trivial wounding of the skin but are also demon-
strable in organ transplantation when the allograft is
chronically rejected and compartments lose, step by
step, their function due to accumulation of ECM.
While hypoxia can cause damage and tissue destruc-
tion, the process of tissue repair and remodeling is also
accompanied by low oxygen levels in certain areas
causing a stress response of fibroblasts and other cell
types involved in tissue remodeling [2].
Tissue damage leads to accumulation of cytokines and
numerous growth factors like members of the trans-
forming growth factor b family (TGF b 1-3) and bone
morphogenetic proteins (BMPs) [3-5]. Another set of
tissue remodeling factors belong to the family of matrix-
metalloproteinases (MMPs) and their inhibitors TIMPs
(tissue inhibitors of metalloproteinases), [6,7]. Compar-
able with MMPs is the action of plasmin and members
of the plasminogen activator urokinase-type (uPA) and
-tissue-type (tPA) which mediate proteolysis of ECM
components but also activation of latent, inactive MMPs
[8,9]. Their negative regulator serine protease inhibitor
(serpin) protein (SERPINE1; plasminogen activator inhi-
bitor-1, PAI-1) is an inhibitor of plasmin action and was
shown to be a target of TGFb-1 which implicates cross-
talks between the members of the pro-fibrotic system
[10,11].
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mRNA molecules and stands for an important cellular
regulatory mechanism. Post-transcriptional regulation of
mRNA by the microRNA (miRNA) system is thereby
highly conserved among species, including humans, and
expression of hundreds of miRNA in tissues and cellular
lineages has already been reported [12]. Transcripts of
miRNA genes form ~ 100 nucleotide-long hairpin pri-
mary miRNA (pri-miRNA) precursors which are subse-
quently translocated from the nucleus to the cytoplasm.
They are further processed to shorter double-stranded
premature miRNA (~ 80 nucleotide-long pre-miRNA)
and finally to mature/functionally active ~ 20 nucleo-
tide-short miRNA species [13]. A given biologically
active miRNA will then be incorporated into the
so-called RNA-induced silencing complex (RISC),
where binding of mRNA targets by miRNA takes
place. Semi-complementary binding of miRNA to the
3’-untranslated region (3’-UTR) of target mRNA results
in translational suppression or cleavage of mRNA,
respectively [13]. Due to these semi-complementary
miRNA-mRNA binding abilities, one miRNA might
control several potential mRNA targets and, vice versa,
one mRNA might be suppressed by several miRNA
species [12].
One particular miRNA was recently shown to be
involved in tissue remodeling and matrix deposition, i.e.
exclusive up-regulation of miRNA-21 by fibroblasts was
shown to be involved in myocardial fibrosis [14]. The
up-regulation of miRNA-21 was suggested to be stress
induced what attracted our attention because the stress
response of fibroblasts on the miRNA level has yet not
been accomplished.
We therefore investigated primary fibroblasts under
hypoxic stress, determined the miRNA profile, and
screened for designated mRNA targets involved in tissue
remodeling and fibrosis development. Lastly, we investi-
gated tissues from kidney transplants showing chronic
remodeling for aberrations in miRNA expression and
impact on designated SERPINE1 mRNA and protein fate.
Methods
Cell lines and culture
Primary human fibroblasts (F-18, dermal origin, kindly
provided by Dr. Miriam Wittmann, Faculty of Biological
Sciences, University of Leeds, UK) and M15D [15] were
cultured as monolayers in RPMI 1640 containing 10%
fetal calf serum (FCS) and 1% antibiotics until subcon-
fluence. Metaphase cytogenetics showed no evidence for
clonal aberrations in these primary cell lines.
Hypoxia in cell culture
Cell culture flasks were placed into anaerobic jars for 24
hours (Anaeropack for cell culture, Mitsubishi Gas
Chemicals, Tokyo, Japan) to induce hypoxic culture
conditions as described [16,17]. Briefly, the Anaeropack
for Cell contains sodium ascorbate as the principal
ingredient which absorbs oxygen and generates carbon
dioxide by oxidative degradation. Magnesium hydroxide
is used as a scavenger for carbon dioxide. These
reagents are located in paper sachets and are placed
into the jars. Controls were cultured in parallel under
normal oxygen concentration of ~ 20%. Viability tests of
cells in culture were performed before and after 24
hours by Trypan blue exclusion.
Transfection of fibroblasts with miRNA-449 inhibitors
and miRNA-449 mimics
The HiPerfect Transfection Reagent (# 301705, Qiagen,
Hilden, Germany) was used for transfection with anti-
hsa-miRNA-449a/b Inhibitor (#MIN0001541, target
sequence UGG CAG UGU AUU GUU AGC UGG U;
#MIN0003327, target sequence AGG CAG UGU AUU
GUU AGC UGG C; respectively, both Qiagen, Hilden,
Germany) or with Syn-hsa-miRNA-449a/b Mimic
(#MSY0001541, target sequence UGG CAG UGU AUU
GUU AGC UGG U; #MSY0003327, target sequence
AGG CAG UGU AUU GUU AGC UGG C; respectively,
both Qiagen, Hilden, Germany). A negative control
siRNA (#1027280; Qiagen, Hilden, Germany) was trans-
fected as well. This control has no homology to any
mammalian gene. Additionally, primary fibroblasts were
treated with the HiPerfect Transfection Reagent only.
Transfection was performed according to the manu-
facturer’s protocol for adherent cells in 6-well plates
with 2 different concentrations as follows: miRNA
inhibitor 50 nM and 100 nM; miRNA mimic 5 nM
and 10 nM, respectively. After transfection cell culture
flasks were placed into anaerobic jars for 24 hours.
Controls were cultured in parallel under normal oxy-
gen tension.
Human tissue specimens
From the archive of the Institute of Pathology, Hann-
over Medical School, we retrieved formalin-fixed, par-
affin-embedded (FFPE) tissues and biopsies from
kidney transplants (n = 5) showing proven histopatho-
logical features of chronic allograft nephropathy with
interstitial fibrosis, glomerular and tubular atrophy
accompanied by only a mild chronic inflammation.
Control samples (n = 4): 2 different tissue specimens
from 1 kidney transplant immediately explanted due to
allograft-steal syndrome, 3 tissue specimens taken from
3 tumor nephrectomies due to renal cell carcinoma.
These control specimens showed normal kidney mor-
phology and no evidence for involvement by carci-
noma. Relevant clinical and morphological information
are listed in Table 1.
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The monolayer of 1 culture flask (75 cm
2) was sus-
pended in 1 ml TRIZOL Reagent (Invitrogen, Carlsbad,
CA, USA) and stored over night at -20°C. The extrac-
tion of total RNA was accomplished as instructed by the
manufacturer. Total RNA was extracted from FFPE tis-
sues following guanidinium isothiocyanate/Proteinase
K-based digestion, and conventional organic extraction
using phenol/chloroform as we previously described
[18].
cDNA synthesis
The TaqMan MicroRNA Reverse Transcription Kit (Part
No. 4366596, Applied Biosystems, Foster City, CA, USA)
and the Megaplex™ RT Primer A (Megaplex™ RT Pri-
mers, Human Pool A, Part No. 4399966, Applied Biosys-
tems, Foster City, CA, USA) were used to synthesize
complimentary DNA (cDNA) for the TaqMan Micro-
RNA Array (TaqMan® Human MicroRNA A Array v2.0,
Part No. 4398965, Applied Biosystems, Foster City, CA,
USA). The final reverse transcription reaction consisted
of 3.0 μL 500 ng total RNA and 4.5 μL RT reaction mix.
cDNA was synthesized as described in the manual of
Run Megaplex™ Pools without pre-amplification
(Applied Biosystems, Foster City, CA, USA).
The TaqMan MicroRNA Reverse Transcription Kit
(Part No. 4366596, Applied Biosystems, Foster City, CA,
USA) was also used to synthesize cDNA for the indivi-
dual TaqMan MicroRNA Assays (RNU48 Assay ID
001006, RNU49 Assay ID 001005, hsa-miRNA-449a
Assay ID 001030, hsa-miRNA-449b Assay ID 001608,
Applied Biosystems, Foster City, CA, USA) by using
0.01 μg total RNA. For real-time RT-PCR on the mRNA
level the High Capacity cDNA Reverse Transcription Kit
(Part No. 4368814, Applied Biosystems, Foster City, CA,
USA) was applied by using 1 μg total RNA.
MicroRNA profiling
The TaqMan Human MicroRNA A Array v2.0 repre-
sents a 384-well format (Part No. 4398965, Applied Bio-
systems, Foster City, CA, USA). 377 human miRNAs,
three endogenous controls and one negative control
Table 1 Condensed data on patients histories and sample type
Gender Age Underlying
disease
Year
of
Tx.
Kidney
explant
or
biopsy
Why
indicated?
Histo-
pathological
diagnosis
Tissue
samples
analyzed
n=
Symbol
#in
Figure 8
female 60 Systemic Lupus
erythematosus
1999* Kidney
explant
(01/2007)
Acute
renal failure
(Interstitial fibrosis, tubular
atrophy)
Banff 2007,
5. II [34]
2 Black circle
Black
square
female 41 Systemic vasculitis (Purpura
Schoenlein-Henoch)
1996 Kidney
explant
(01/2007)
Acute
renal failure
(Interstitial fibrosis, tubular
atrophy)
Banff 2007,
5. II [34]
1 Black
triangle
male 17 Obstructive
uropathy
2006* Kidney
explant
(08/2007)
Impaired
kidney
function
(Interstitial fibrosis, tubular
atrophy)
Banff 2007,
5. III [34]
2 Black
reverse
triangle
Black
rhomb
female 45 Chronic glomerulo-nephritis 1996 Indication
biopsy
(04/2007)
Impaired
kidney
function
Chronic tubulo-interstitial
injury,
evidence for calcineurin
inhibitor
toxicity (CNIT)
1 White
circle
male 72 Chronic interstitial nephritis 2007 Indication
biopsy
(06/2007)
Impaired
kidney
function
Interstitial fibrosis, tubular
atrophy, vasculopathy)
Banff 2007,
5. II [34] **
1 White
square
female 42 Systemic Lupus
erythematosus
2005 Kidney
explant
(2005)
Allograft-steal-
syndrome
Diffuse tubular
damage
2 Black
circles
in plot
“Control”
Not known
RCC
Tumor
RCC 1
(anonymized) RCC n.a. nephrectomy RCC Normal 1
RCC RCC 1
2
nd allograft in patients history, ** = “old-for-old” kidney allocation, Tx. = transplantation, RCC = renal cell carcinoma, n.a. = not attributable.
#Two symbols per
case mean that 2 different tissue blocks were analyzed in the same patient.
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450 μL TaqMan Universal PCR Master Mix, No
AmpErase UNG (Part No. 4324018, Applied Biosystems,
Foster City, CA, USA), 6 μL Megaplex RT product and
444 μLH P L C - H 2O. The TaqMan Human MicroRNA A
Array was performed on a 7900HT Fast Real-Time PCR
system and was recorded by the 7900HT SDS 2.3 soft-
ware (Applied Biosystems, Foster City, CA, USA). Only
miRNA showing at least 3-fold increase or decrease
were included in the results section. LDA data of
miRNA expression are shown in the additional file 1.
Gene expression profiling by custom made low
density arrays
A set of 45 genes related to tissue remodeling and fibro-
sis and 2 reference genes (RNA-polymerase 2 - POLR2A
and b-Glucuronidase - GUSB) was selected for custom
made TaqMan Low Density Arrays (LDA; Applied Bio-
systems, Foster City, CA, USA). Details of the genes
s p o t t e do nt h eL D Aa r es h o w ni nt h ea d d i t i o n a lf i l e2 .
The reference gene Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was declared to be mandatory on
LDA according to the distributor but due to the well
known up-regulation of GAPDH by hypoxia it was not
considered as a reference gene for subsequent relative
quantification. The entire gene set was spotted 8-fold
(8 × 48) on the 384-well micro fluidic card allowing
concomitant investigation of 8 samples per run. The
array was loaded with a mixture of 5 μLc D N A ,4 5μL
HPLC-H2O (J.T. Baker, Phillipsburg, NJ, USA) and 50
μL Universal PCR Master Mix (Part No. 4352042,
Applied Biosystems, Foster City, CA, USA). TaqMan
low density arrays were performed on a 7900HT Fast
Real-Time PCR system and recorded by the 7900HT
SDS 2.3 software (Applied Biosystems, Foster City, CA,
USA). Only genes showing at least 3-fold up- or down-
regulation were included in the results section. LDA
data of mRNA expression are shown in the additional
file 1.
Re-evaluation of miRNA and mRNA targets
The expression of hsa-miRNA-449a (ID 001030) and
hsa-miRNA-449b (ID 001608) along with reference small
RNA molecules RNU48 (ID 001006) and RNU49 (ID
001005) was re-evaluated by real-time PCR (TaqMan
7500 Fast Real-Time PCR system, Applied Biosystems).
Each reaction consisted of 10 μL TaqMan Universal PCR
Master Mix, No AmpErase UNG (Part No. 4324018,
Applied Biosystems, Foster City, CA, USA), 1 μLo ft h e
invidual TaqMan MicroRNA Assay (Applied Biosystems,
Foster City, CA, USA), 4 μL HPLC-H2O( J . T .B a k e r ,
Phillipsburg, NJ, USA) and 5 μL cDNA.
The re-evaluation of SERPINE1 mRNA expression was
performed with 2 different assays (Hs01126606_m1,
Hs00167155_m1, respectively, Applied Biosystems, Fos-
ter City, CA, USA) in addition to POLR2A
(Hs00172187_m1) and GUSB (Hs99999908_m1) as
reference genes in 20 μL reactions containing 10 μL
TaqMan Gene Expression Master Mix, 1 μL of the indi-
vidual TaqMan Gene Expression Assay (both Applied
Biosystems), 8 μL pure water, and 1 μL cDNA.
Quantification of real-time PCR data
Recorded CT values were converted into ΔCT values
relative to reference genes POLR2A and GUSB for
mRNA and RNU48 and RNU49 for microRNA, respec-
tively. The 2
-ΔΔCT method [19] was applied by using
Excel 8.0 (Microsoft, Redmond, WA, USA). Results
were statistically analyzed and graphically visualized
with Prism 5.0 (GraphPad Software, San Diego, CA,
USA) by applying the one-way analysis of variance
(ANOVA) test followed by Tukey’s post-test.
Immunocytochemistry and immunohistochemistry
F-18 and M15D were transfected as described and cul-
tured as monolayers on 4-well chamber slides (Nalge
Nunc, Naperville, IL, USA) under hypoxia for 24 hours.
Primary human fibroblasts were treated with the HiPer-
fect Transfection Reagent only and cultured under nor-
mal oxygen tension. Fixation was carried out in ice-cold
acetone for 10 minutes followed by air-drying and rehy-
dration in PBS. The chamber slides were incubated for
1 h with the mouse monoclonal anti-human SERPINE1
antibody raised against amino acids 1 - 250 of the
mature protein (1:50 dilution; TJA6, sc-59636, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA). For
visualization the ZytoChem Plus HRP Polymer-Kit
(Zytomed Systems, Berlin, Germany) and the DAB Sub-
strate Kit High Contrast (Zytomed) were used. Counter-
staining was accomplished with haematoxylin.
Immunohistochemistry on human kidney tissue was
performed on tissue sections (1 - 2 μm) which were
deparaffinised and treated with 3% H2O2 for 10 min.
Following pre-treatment in a pressure cooker for retrie-
val of antigens, sections were incubated for 1 hour with
the antibody against SERPINE1. Positive control for
SERPINE1 was human placenta tissue and an isotype
control monoclonal antibody (1:100 dilution, negative
control for mouse IgG1 Ab-1, clone NCG01, DLN-
05791, dianova, Hamburg, Germany) was used as nega-
tive control in lieu of the primary antibody.
Results
Hypoxia induced down-regulation of miRNA in primary
fibroblasts
MicroRNA profiling determined that only 3 out of 377
miRNA subtypes were down-regulated in primary fibro-
blasts under hypoxic conditions compared with primary
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miRNA-449a (median -10.2, range -9.1 up to -11.3,
p < 0.001), miRNA-449b (median -2.6, range -1.4 up to
-3.8) and miRNA-518a-3p (median -5.1, range -2.3 up
to -7.9, p < 0.01), Figure 1.
Re-evaluation in an independent experimental set-
ting confirmed down-regulation of miRNA-449a
(median -4.0, range -2.9 up to -5.0, p < 0.01) and
miRNA-449b (median -3.6, range -2.3 up to -4.9,
p < 0.01), Figure 2.
SERPINE1 is the most up-regulated gene in primary
fibroblasts cultured under hypoxic conditions
Hypoxia induced overexpression of 10 target genes com-
pared with gene expression profiling under normal oxy-
gen conditions: Among those, SERPINE1 was
significantly overexpressed by up to 10-fold (p < 0.001).
Other inducible factors were COL4A3, LOX, PLAT,
PLAUR, PLOD2, EDN1, GAPDH and inhibitors of
matrix remodeling NOG and TIMP1. BMP6 and
FOXP3 were down-regulated (Figure 3).
Target prediction for miRNA-449a/b revealed SERPINE1
mRNA as a candidate
From the hypoxia-induced set of aberrantly expressed
genes in fibroblasts (Figure 3) we screened for those
potentially targeted by miRNA-449a/b. The TargetScan
Database (http://microrna.sanger.ac.uk/targets/v5/, Well-
come Trust Sanger Institute) revealed SERPINE1 as a
predicted target for both miRNA-449a and miRNA-
449b (additional file 3 A + B).
SERPINE1 overexpression in fibroblasts was then re-
evaluated with 2 different commercially available gene
expression assays following hypoxic culture in 3 inde-
pendent experiments. Both assays confirmed SERPINE1
overexpression compared with normal oxygen condi-
tions (median 5.3, 8.0, respectively), Figure 4.
Hypoxia-driven inhibition and mimicking of miRNA-449
revealed direct targeting of SERPINE1 mRNA in vitro
Transfection followed by culture under hypoxic condi-
tions induced increase and decrease of miRNA-449a/b
by inhibition and mimicking, respectively. Inhibition
Figure 1 MiRNA profiling and identification of candidates in fibroblasts under hypoxia. MiRNA profiling of a total of 377 different miRNA
species revealed down-regulation of miRNA-449a, -449b and -518a-3p when primary fibroblasts were cultured under hypoxic conditions (relative
to RNU48). Shown are results from cell line F-18. *** = p < 0.001, ** = p < 0.01 (two independent experiments).
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down-regulation under hypoxia. All calculations were performed relative to RNU48 in the cell line F-18. ** = p < 0.01.
Figure 3 Gene expression profiling in fibroblasts under hypoxia. Primary human fibroblasts were analysed by LDA designed to determine
fibrosis- and ECM-related gene expression. Depicted are the mean and range of gene expression in fibroblasts under hypoxia relative to
reference gene POLR2A. Shown are results from cell line F-18. Among other factors induced in the hypoxic culture SERPINE1 mRNA was
increased 10-fold. *** = p < 0.001, ** = p < 0.01 (two independent experiments).
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fold and 15-fold, for miRNA-449b by up to 26-fold and
27-fold (50 nM, 100 nM, respectively). Mimicking
increased miRNA-449a by up to 8-fold and 15-fold, for
m i R N A - 4 4 9 bb yu pt o6 - f o l da n d4 - f o l d( 5n M ,1 0n M ,
respectively), Figure 5.
In a next step fibroblasts were studied for SERPINE1
mRNA expression under the similar experimental set-
ting. When transfection studies were performed under
h y p o x i aa ni n c r e a s eo fS E R P I N E 1m R N Ab yu pt o8 . 0 -
fold (miRNA-449a inhibition: median 7.2, range 6.5 to
8.0; miRNA-449b inhibition: median 7.1, range 6.2 to
8 . 5 )c o u l db ed e m o n s t r a t e dc o m p a r e dw i t hn o n - t r a n s -
fected cells cultured under hypoxia. Mimicking of
miRNA-449a/b reversed SERPINE1 mRNA level thereby
providing direct evidence for a targeting of SERPINE1
mRNA by miRNA-449a/b, Figure 6. The effects shown
for SERPINE1 targeting by miRNA-449a/b were exclu-
sively demonstrable in the hypoxic state of cell culture.
Inhibition and mimicking of miRNA-449 affected
SERPINE1 protein expression in fibroblasts
Following transfection with miRNA-449a inhibitor fibro-
blasts were cultured under hypoxic conditions and
showed a strong induction of SERPINE1 protein (Figure
7A + B). By contrast, miRNA-449a mimics (Figure 7C +
D) showed almost no SERPINE1 protein expression
whereas control fibroblasts showed a faint SERPINE1
staining (Figure 7E + F).
Chronic allograft remodeling showed the inverse
expression of miRNA-449a/b and SERPINE1 expression
In human kidney transplants showing chronic allograft
remodeling, miRNA-449a and miRNA-449b were down-
regulated by up to 17.0-fold (median -7.8, range -2.5 to
-16.6, p < 0.001) and 95.0-fold (median -23.3, range 2.3
to -95.4, p < 0.05), respectively (Figure 8 B + C). SER-
PINE1 mRNA expression in these specimens were
increased by up to 37.0-fold (median 15.62, range 3.2 to
Figure 4 Re-evaluation of SERPINE1 mRNA expression in fibroblasts under hypoxia. Two different gene expression assays were applied to
confirm SERPINE1 overexpression relative to POLR2A in fibroblasts cultured under hypoxia compared with fibroblasts cultured under normal
oxygen conditions. Shown are results from cell line F-18. * = p < 0.05 (three independent experiments).
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Figure 8A.
SERPINE1 protein in kidney tissues was predomi-
nantly demonstrable in areas of interstitial fibrosis and
vascular remodeling. Activated fibroblasts and smooth
muscle cells were labeled. Glomerula and atrophic tubuli
r e m o d e l e db yc o n n e c t i v et i s s u ew e r ea l s os t r o n g l y
stained (Figure 9A + B). Control kidney affected by
acute diffuse tubular damage showed a heterogenous
pattern with some strongly labeled proximal tubuli
whereas other compartments were almost unlabelled.
Some smooth muscle cells in smaller arterial vessels
were also stained for SERPINE1 (Figure 9, C + D).
Discussion
Uncontrolled tissue remodeling affects organ function, e.
g. leads to dysfunction in transplanted organs. Acute tis-
sue damage and wounding but also consecutive tissue
repair and remodeling create a hypoxic environment
and provide an appropriate condition for changes in
gene expression due to hypoxia-sensitivity [20]. The
fibroblast is the leading cell type involved in production
of ECM following an adequate stimulus, i.e. one single
activated fibroblast is able to induce thousands of pro-
collagen molecules per minute [21]. It is the nature of
tissue repair and remodeling that numerous factors and
environmental conditions act in concert to guide the
restoration process such as expression of hypoxia-indu-
cible factors (HIF) and their target genes but also
growth factors which induce a pro-fibrotic response [1].
Accordingly, at a glance it appears unlikely that a single
aberration is predominantly involved in abnormal tissue
remodeling. However, it has recently been shown by a
decisive study that overexpression of miRNA-21 in
fibroblasts is involved in myocardial fibrosis [14] sug-
gesting that stress signaling could affect miRNA
expression.
We found by miRNA profiling that only 3 out of 377
miRNA subtypes were down-regulated in primary fibro-
blasts when the stress factor hypoxia was tested. A sin-
gle miRNA, i.e. the miRNA-184 was up-regulated (data
not shown). The profiling showed no notable up-regula-
tion of miRNA-21 in our approach. Previous work in
cancer cell lines showed a much stronger affection by
Figure 5 MiRNA-449a/b expression under hypoxia. Primary human fibroblasts were transfected with miRNA-449a/b inhibitor or miRNA-449a/
b mimics and were cultured under hypoxia. Inhibition or mimicking strongly decreased or increased miRNA-449a/b expression, respectively.
Depicted are calculations relative to reference gene RNU48 compared with non transfected cells cultured with hypoxia. Negative control means
cells transfected with negative control siRNA only. Results are shown for cell line F-18 but were likewise demonstrable in M15D. * = p < 0.05
(three independent experiments).
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regulated [22,23]. This difference can be explained by
the fact that the basic miRNA profile in carcinoma cells
is apparently much more aberrant than in normal cells
and furthermore likely to be amplified by additional
stress factors such as hypoxia.
We used only Pool A and therefore only 377 miRNA
for profiling because trials in our lab using also Pool B
showed very low numbers of detectable miRNA in dif-
ferent tissues and cell lines tested.
We selected the clustered miRNA subtypes miRNA-
449a/b for confirmatory experiments in hypoxic fibro-
blasts because this decrease should lead to up-regulation
of certain mRNA targets in this setting. Additionally,
due to the immediate availability of low-density arrays
designed to reveal important players in the pathogenesis
of myelofibrosis [24] we performed gene expression pro-
filing in hypoxic fibroblasts. Among other up-regulated
factors involved in ECM synthesis and remodeling
including HIF-1a targets LOX, EDN1 and GAPDH,
SERPINE1 showed the strongest induction by up to
10-fold.
I nt h en e x ts t e pw ea s k e di fo n eo ft h e s eh y p o x i a -
inducible factors could be regulated by miRNA-449a/b.
The miRBase Target Database (by using the link for
TargetScan) listed SERPINE1 as a putative mRNA target
of miRNA-449a/b.
We then tested the functional relationship between
SERPINE1 and miRNA-449a/b by transfection of fibro-
blasts with miRNA-449 inhibitors or the respective
mimics. SERPINE1 mRNA strongly increased through
miRNA-449 inhibition while miRNA-449 mimics
restored to baseline SERPINE1 mRNA levels. Of note,
targeting of SERPINE1 mRNA by miRNA-449a/b was
only demonstrable when hypoxia was present.
Though an increase of SERPINE1 could easily be
explained by induction through HIF-1a the experiments
using miRNA-449a/b mimics definitely support our pro-
posed mechanism because these mimics induced a
decrease of SERPINE1 mRNA level. Accordingly, label-
ing of SERPINE1 protein in these cell cultures con-
firmed a strong SERPINE1 protein expression when
miRNA-449a was inhibited. When miRNA-449a was
mimicked, almost no staining was demonstrable.
Figure 6 SERPINE1 mRNA level in fibroblasts under hypoxia. Transfection of miRNA-449a/b inhibitors and miRNA-449a/b mimics targeted
SERPINE1 mRNA under hypoxic culture conditions. The mimicking of miRNA-449a/b reversed SERPINE1 mRNA to baseline level. Depicted are
calculations relative to reference gene POLR2A compared with non-transfected cells cultured under hypoxia. Negative control means cells
transfected with negative control siRNA only. SERPINE1 mRNA induction through hypoxia alone and without additional transfection of miRNA-
449 inhibitors or miRNA-449 mimics is indicated by the dotted line (cell line F-18). ** = p < 0.01 (three independent experiments).
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Page 9 of 14Figure 7 Immunocytochemistry of primary human fibroblasts (F-18) transfected with miRNA-449a inhibitor or miRNA-449a mimics.
SERPINE1 strongly marked the fibroblasts transfected with miRNA-449a inhibitor (Figure 7 A + B) compared to miRNA-449a mimics which
virtually blocks SERPINE1 protein expression (Figure 7 C + D). Non transfected primary human fibroblasts cultured under hypoxia showed
SERPINE1 protein labeling in some cells (Figure 7 E + F). DAB immunostaining with mAb against SERPINE1 protein counterstained with
haematoxylin. Magnification in Figure 7 A, C, E: 100×; Figure 7 B, D, F: 200×; brown: SERPINE1 positive fibroblasts; blue: nuclei (two independent
experiments).
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Page 10 of 14The knowledge on miRNA-449 action in humans is
limited. In mice, the miRNA-449 was shown to be
involved in the development of the choroid plexus [25].
In a model of post-ischemic regeneration in mice and
patients with Duchenne muscular dystrophy miRNA-
449 was induced and therefore referred to be a “regen-
erative miRNA” [26]. So it will be a matter of future
efforts to test the dynamics of miRNA-449 expression
during ischemia/hypoxia and post-hypoxia conditions, i.
e. do miRNA-449a/b increase to normal levels when
cells were exposed to normal oxygen levels?
We subsequently transferred the finding of inverse
expression of miRNA-449/SERPINE1 to an in vivo set-
ting, i.e. chronic allograft remodeling in kidney trans-
plants. We assumed that initial tissue damage and
ongoing tissue remodeling generate an environment
with hypoxia, at least in certain areas, which affects
miRNA-449 and SERPINE1 expression. Indeed, an
inverse expression of miRNA-449a/b and SERPINE1
mRNA expression could be demonstrated in almost all
patient samples. Apparently, a case-specific down-regu-
lation of miRNA-449a/b expression must not necessarily
correlate with the level of increased SERPINE1 mRNA.
Consequently, morphological detection of the miRNA of
interest should have been the next step. However,
miRNA detection by e.g. in-situ-hybridization is more
promising when the target of interest is expressed at
considerable high levels what did not hold true for
decreased miRNA-449. So we decided to look for the
cellular source of SERPINE1 overexpression by immu-
nohistochemistry. Because SERPINE1 mRNA and pro-
tein is undetectable in healthy kidney tissue [27] we
selected a kidney with an acute diffuse tubular damage
known to express SERPINE1 [28]. Kidney tubuli were
labeled for SERPINE1 in a patchy pattern but clearly
sparing all other compartments except for rarely stained
smooth muscle cells of smaller vessels. By contrast, kid-
ney allografts showed strong SERPINE1 labeling predo-
minantly in activated fibroblasts and smooth muscle
cells in areas of fibrotic and vascular remodeling, in
atrophic tubuli and in the mesangium of glomeruli.
Even though barely demonstrable, some inflammatory
cells in the kidney transplants were also SERPINE1
positive.
SERPINE1 is known to be induced in kidney disease
including kidney fibrosis and chronic allograft dysfunc-
tion [reviewed in [29]. SERPINE1 expression is inducible
by numerous stimuli most notably by hypoxia and reac-
tive oxygen species (ROS) themselves. However, in
chronic hypoxia HIF-1a is no longer present [30] and
thus can hardly be the inducer of SERPINE1 expression
in a chronic remodeling process. TGFb-1 can induce
SERPINE1 expression but is inversely controlled by
SERPINE1 via plasmin action [31]. Expression of tumor
Figure 8 Increased expression of SERPINE1 mRNA (A) and
down-regulation of miRNA-449a/b (B + C) in human kidney
transplants. All cases showed an inverse mode of expression.
Symbols represent the mean of 3 independent quantitative analyses
of tissue blocks or biopsies as indicated in Table 1. The mean
expression of SERPINE1 and miRNA-449a/b in the control kidney
samples was arbitrarily set to 1. * = p < 0.05; ** = p < 0.01;
*** = p < 0.001.
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Page 11 of 14necrosis factor, driven by inflammation, can induce SER-
PINE1 [32] but apart from some scattered inflammatory
cells inflammation was not the predominant feature in
our samples.
Regulation of the SERPINE1 molecule is mainly
achieved at the transcriptional level and the gene con-
tains binding sites for several transcription factors such
as Smads and HIFs [29]. However, the knowledge on
post-transcriptional regulation of SERPINE1 mRNA is
sparse. SERPINE1 mRNA contains several AU-rich
destabilizing elements in the 3’-UTR suggesting a quick
turnover. Interestingly, a recent study used a model of
kidney fibrosis in rats to show that angiotensin II is able
to stabilize SERPINE1 mRNA via the ubiquitous RNA-
binding protein human-antigen R (HuR), [33].
We present a novel mechanism of post-transcriptional
control of SERPINE1 where miRNA-449a/b lost the
control over SERPINE1 mRNA through down-regulation
under hypoxic conditions. If hypoxia-inducible factors
themselves or hypoxia-triggered epigenetic mechanisms
such as hypermethylation [30] interfere with miRNA-
449a/b expression is a matter of ongoing investigations.
Conclusions
We conclude that during remodeling of organs and tis-
sues which lack the capability for self-renewal the nor-
mally tightly controlled and concerted action of
different factors may be affected by aberrantly expressed
miRNA species lastly leading to fibrosis development.
As shown for hypoxia, decreased miRNA-449a/b
Figure 9 Immunohistochemistry of kidney transplants showing chronic allograft remodelling revealed a strong labelling of SERPINE1
protein expression in areas of interstitial fibrosis and vascular remodelling (black arrows in A, white arrows in B). SERPINE1 positive
cells were activated fibroblasts, endothelial cells and smooth muscle cells, Figure 9 A (magnification 100×). In not fully remodelled functional
compartments glomerula and mesangial cells were prominently labeled (black arrow in B, magnification 200×). If present, scattered inflammatory
cells stained SERPINE1 positive. In the control tissue derived from a kidney with acute tubular damage selected to ensure SERPINE1 expression
only proximal tubuli (black arrows in D) were labelled in a considerable heterogenous pattern. Except for some smooth muscle cells SERPINE1
spares all other compartments (Figure 9C, D - magnification 25×, 100×, respectively). DAB immunostaining with mAb against SERPINE1 protein.
Brown: SERPINE1 positive cells; blue: nuclei (two independent experiments).
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Page 12 of 14contributes to increased SERPINE1 level due to
impaired miRNA control of SERPINE1 mRNA fate
in vitro and potentially likewise in vivo.T h i sn o v e l
mechanism is demonstrable in chronic allograft remo-
deling of the kidney but probably also in other organ
fibrosis and should be considered as a potential target
for therapeutic intervention.
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